Seaport Therapeutics, Inc. Common Stock (SPTX) — Working Capital to Net Assets Ratio
Seaport Therapeutics, Inc. Common Stock (SPTX) has a Working Capital to Net Assets ratio of 63.1% as of June 2026. Working capital of $266.50 Million (current assets of $282.18 Million minus current liabilities of $15.67 Million) is measured against net assets of $422.60 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See operational self-sufficiency of Seaport Therapeutics, Inc. Common Stock to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Seaport Therapeutics, Inc. Common Stock Working Capital to Net Assets (2024–2025)
This chart shows how Seaport Therapeutics, Inc. Common Stock's Working Capital to Net Assets ratio has evolved across 2 annual periods from 2024 to 2025. As of June 2026, the ratio stands at 63.1%, reflecting working capital of $266.50 Million against net assets of $422.60 Million USD. For the complete balance sheet picture, see SPTX current and non-current assets.
Annual Working Capital to Net Assets for Seaport Therapeutics, Inc. Common Stock (2024–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Seaport Therapeutics, Inc. Common Stock from 2024 to 2025, covering 2 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check financial resilience of Seaport Therapeutics, Inc. Common Stock to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -227.4% | $210.45 Million | $-92.55 Million | $223.23 Million | $12.78 Million | ▲ +975.9 pp |
| 2024 | -1203.3% | $299.00 Million | $-24.85 Million | $310.15 Million | $11.15 Million | — |